Business
Cytokinetics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to
About this update from Cytokinetics, Incorporated
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences in November: UBS BioPharma Conference on Wednesday, November 8, 2023 at 1:00 PM Eastern Time in a fireside chat with Fady I. Malik, Executive Vice President of Research & Development, and Andrew Callos, Executive Vice President, Chief Commercial Officer, at the Fontainebleau Miami Beach in Miami Beach, FL.Truist Securities BioPharma Symposium on Thursday, November 9, 2023 at 10:45 AM Eastern Time in a panel discussion, entitled “Muscle Matters: Innovative Approaches to Targeting Cardiac & Skeletal Muscle,” with Fady I. Malik, Executive Vice President of Research & Development, at the Lotte New York Palace in New York, NY.Jefferies London Healthcare Conference Healthcare Conference 2023 on Tuesday, November 14, 2023 at 11:00 AM Greenwich Mean Time in a fireside chat with Robert I. Blum, President and Chief Executive Officer, at The Waldorf Hilton in London, England.35th Annual Piper Sandler Healthcare Conference on Tuesday, November 28, 2023 at 12:30 PM Eastern Time in a fireside chat with Robert I. Blum, President and Chief Executive Officer, and Fady I. Malik, Executive Vice President of Research & Development, at the Lotte New York Palace in New York, NY. Interested parties may access the live webcasts of the fireside chats and panel discussion by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replay will be archived on the Cytokinetics website for 90 days following the conclusion of the event. About Cytokinetics Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Aficamten is a next-in-class cardiac myosin inhibitor, currently the subject of three Phase 3 clinical trials: SEQUOIA-HCM, evaluating aficamten in ...